End of Medicare Part D Subsidy: Implications for Seniors

The end of Medicare Part D’s temporary premium subsidy after 2026 could turn the 2027 enrollment season into a much bigger shopping event for millions of Medicare beneficiaries and the agents, agencies, and carriers that serve them.

The Centers for Medicare & Medicaid Services has confirmed that the Part D Premium Stabilization Demonstration will conclude at the end of 2026. The program was created to soften premium volatility as Medicare implemented major prescription drug benefit changes under the Inflation Reduction Act, and it provided billions of dollars in additional federal support to stand-alone prescription drug plans.

For 2026 alone, the program is estimated to cost the federal government roughly $3.6 billion. Its disappearance does not mean every beneficiary will receive a dramatic premium increase in 2027. It does mean, however, that the market will lose a financial buffer that has been absorbing part of the cost pressure faced by stand-alone Part D plans.

Why the Subsidy Existed in the First Place

Understanding the decision requires looking back at the redesign of Medicare Part D. Beginning in 2025, the Inflation Reduction Act substantially changed how prescription drug expenses are divided among beneficiaries, insurers, drug manufacturers, and the federal government.

One of the most visible changes was a new annual limit on beneficiaries’ out-of-pocket spending for covered Part D drugs. The limit was $2,000 in 2025 and increased to $2,100 for 2026. It is expected to rise to $2,400 in 2027. That protection can be extremely valuable for people taking high-cost medications, but the redesigned benefit also shifted a larger portion of prescription drug liability to private Part D plan sponsors.

That created concern that insurers would respond with substantial premium increases or that some carriers would reduce their presence in the stand-alone Part D market. CMS responded with the voluntary Premium Stabilization Demonstration.

During the program’s first year, CMS reduced the base beneficiary premium used in plan calculations by $15 and limited the year-over-year premium increase for participating plans to $35 per month. For 2026, federal support was scaled back. The base premium reduction fell to $10 and the maximum allowable monthly increase rose to $50.

In other words, the government had already begun gradually removing the stabilization measures before announcing their complete expiration after 2026.

CMS Says the Market Is Ready to Stand on Its Own

CMS says its analysis of insurers’ 2027 bids indicates that Part D sponsors now have enough experience with the redesigned benefit to accurately estimate prescription drug utilization and costs. The agency says that makes the additional demonstration support unnecessary and allows the stand-alone Part D market to return to traditional operating conditions.

Administration officials have also argued that the subsidies could create distorted incentives. One official told The Wall Street Journal that insurers could increase premiums knowing the federal government would absorb part of the additional cost.

CMS has emphasized that consumers should continue to have access to lower-cost choices, particularly if they actively compare plans rather than automatically renewing their existing coverage.

“Every Medicare beneficiary still has access to low-cost plans, and we will continue to lower prescription drug prices for every American patient.”

That distinction is important for insurance professionals. The story is not simply that Medicare Part D premiums are going up. The more accurate message is that premiums are likely to become more variable, and beneficiaries may need to pay greater attention to which plan they choose.

Nearly 25 Million Stand-Alone Plan Enrollees Are in the Conversation

KFF reports that 24.9 million people were enrolled in stand-alone Medicare prescription drug plans in 2026, up from 23.2 million in 2025. Another 31.4 million people received Part D coverage through Medicare Advantage plans.

The financial difference between those two markets is already significant. KFF calculated that the average monthly premium for stand-alone Part D coverage was about $36 in 2026, compared with approximately $8 for the prescription drug portion of Medicare Advantage plans. Medicare Advantage insurers can use rebate dollars to reduce or eliminate Part D premiums, an option unavailable to stand-alone PDP sponsors.

The temporary subsidy helped narrow some of the pressure on stand-alone plans. According to analysis cited by KFF from the Medicare Payment Advisory Commission, the demonstration reduced the average stand-alone Part D premium by approximately $26 per month in 2025 and $16 per month in 2026.

That does not mean removing the subsidy will automatically add $16 to every beneficiary’s monthly bill. Premiums are calculated plan by plan and vary significantly by market. But the figures illustrate how much federal support has been sitting behind the prices consumers currently see.

Premiums Are Only Part of the Story

For agents discussing the change with clients, focusing exclusively on the monthly premium could create a misleading comparison. Insurers facing higher prescription costs have several tools available beyond increasing premiums.

They can change deductibles, adjust formularies, modify preferred pharmacy arrangements, increase coinsurance, strengthen utilization management, or reposition products altogether. KFF found that most Part D enrollees already faced either the standard $615 deductible or a partial deductible in 2026, while coinsurance has become increasingly common for brand-name and non-preferred medications.

That makes total annual cost more important than the premium printed at the top of the plan comparison.

“What’s going to matter most for consumers is how much more or less they have to pay at the end of a month.”

The Competitive Landscape Is Getting More Concentrated

The subsidy decision also arrives during a period of consolidation and shrinking choice in the stand-alone Part D market.

KFF found that the average Medicare beneficiary had access to about 30 stand-alone Part D plans in 2021. By 2025, that number had fallen to 14. The number of premium-free benchmark plans available to beneficiaries receiving the Part D Low-Income Subsidy also declined sharply during that period.

At the same time, market share has become increasingly concentrated. In 2026, the five largest Part D organizations accounted for roughly 74% of all Part D enrollment. Centene alone represented about 35% of stand-alone PDP enrollment, while CVS Health and UnitedHealth also held substantial positions.

This matters because premium pressure does not occur in isolation. If some carriers decide that certain markets or product designs no longer generate acceptable returns, agents could face fewer plans to recommend and beneficiaries could face fewer meaningful alternatives.

Medicare Advantage Could Become More Attractive, but It Is Not an Automatic Substitute

One of the most important strategic questions for insurers is whether rising stand-alone Part D premiums accelerate movement toward Medicare Advantage.

The economics make that possibility difficult to ignore. Many Medicare Advantage plans include prescription drug coverage with little or no additional Part D premium. A beneficiary comparing that option with a stand-alone drug plan carrying a noticeably higher monthly premium may naturally ask whether switching makes sense.

But an agent should resist reducing the decision to premium alone. Traditional Medicare paired with a stand-alone PDP and potentially a Medicare supplement policy is fundamentally different from Medicare Advantage. Provider networks, prior authorization, cost sharing, supplemental benefits, travel considerations, and Medigap eligibility can all affect the decision.

That makes 2027 an opportunity for professional advice, not simply product replacement.

Rural Markets Deserve Extra Attention

The potential effects could also vary considerably by geography. Stand-alone Part D coverage plays an especially important role among beneficiaries who remain in traditional Medicare, including many people living in rural communities.

KFF has previously found that nearly six in ten Part D enrollees living in the nation’s most rural areas relied on stand-alone prescription drug plans. At the same time, rural consumers generally have fewer Medicare Advantage choices and may encounter narrower provider networks.

For agencies operating in rural markets, that means fewer PDP choices or significant premium changes could have an outsized impact. Local market analysis will matter much more than national averages.

Four Conversations Agencies Should Prepare for This Fall

Final 2027 plan premiums and market offerings are expected to become available in September, giving agencies a relatively short window to understand changes before Medicare’s annual enrollment period begins. Training producers before client questions arrive can make those conversations substantially easier.

• Renewal reviews: Encourage existing PDP clients to compare rather than automatically renew.
• Total drug costs: Compare premiums, deductibles, formularies, pharmacies, coinsurance, and medications together.
• Coverage alternatives: Explain Medicare Advantage tradeoffs without treating lower premiums as automatically better.
• Financial assistance: Screen appropriate clients for Extra Help and other available assistance.

That last conversation could become especially important. KFF reports that 13.6 million Part D beneficiaries received the Low-Income Subsidy in 2026. Eligible beneficiaries can receive assistance with both premiums and prescription cost sharing, making awareness of the program increasingly valuable when household budgets are tight.

What Carriers and Distribution Leaders Should Be Watching

For carriers, the end of the demonstration represents more than a pricing change. It is effectively a test of how the redesigned Part D market performs without extraordinary federal stabilization.

Pricing teams will need to balance premium competitiveness against rising prescription drug liability. Distribution leaders will need to watch whether higher stand-alone premiums change consumer behavior. Medicare Advantage organizations may see new acquisition opportunities, while PDP-focused carriers may put greater emphasis on retention, formulary design, preferred pharmacy relationships, and disciplined market selection.

Agencies should also pay close attention to product exits and consolidations. A carrier leaving a region can create substantially more disruption than a modest premium increase because affected beneficiaries must make an active coverage decision.

Meanwhile, increased movement among plans could create heavier service demands for agencies. Prescription lists need to be updated. Pharmacy preferences need to be verified. Clients may need more explanation of deductibles and coinsurance. Agents who normally handle straightforward renewals could find themselves conducting considerably more detailed comparisons.

The Biggest Risk May Be Consumer Confusion

The Medicare market already asks consumers to navigate premiums, deductibles, formularies, coverage phases, pharmacy networks, utilization management, and multiple types of Medicare coverage. Removing a temporary subsidy adds another moving piece, but most beneficiaries will never need to understand the mechanics of the federal demonstration itself.

They will simply notice that a plan costs more, costs less, disappears, or changes its benefits.

That is where agents can add real value. Rather than leading with a complicated policy explanation, start with the practical question: What changed for this client?

A $7 monthly increase may be insignificant for one beneficiary and meaningful for another. A cheaper plan may look attractive until the client discovers that a critical medication has moved to a different formulary tier. A Medicare Advantage option may have a compelling premium but exclude an important specialist from its network.

The right answer will continue to depend on the individual.

2027 Could Reward the Agencies That Prepare Early

CMS has already established the 2027 national base beneficiary premium at $41.33, up from $38.99 in 2026, reflecting the statutory limit that caps annual growth in the base premium at 6% through 2029. But that national figure is only a starting point. Actual plan premiums can differ substantially, and the elimination of the separate stabilization demonstration means consumers could see greater variation among plans.

The full picture will become clearer when CMS releases finalized 2027 Medicare Advantage and Part D plan information in September.

Until then, agencies do not need to predict exactly where premiums will land. They do need to prepare producers for a year in which familiar plans may look different, premium comparisons may matter more, and beneficiaries may have stronger incentives to shop.

For an industry built around helping clients navigate risk and uncertainty, that is familiar territory. The agencies that translate this policy change into clear, individual guidance will be in the best position to protect existing relationships while helping Medicare consumers make informed decisions about 2027 coverage.